DOGLIOTTI, Luigi
DOGLIOTTI, Luigi
Dip. SCIENZE CLINICHE E BIOLOGICHE (attivo dal 01/01/1900 al 30/04/2013)
Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study
2012-01-01 Brizzi MP; Fazio N; Ferrero A; Nobili E; Volante M; Tozzi L; D'Avolio A; Milanesi E; Dogliotti L; Berruti A
Case-control study of the impact of adjuvant hormone therapy in prostate cancer patients on quality of life, anxiety and depression and self body image perception
2008-01-01 Saini A; Ostacoli L; Negro M; Sguazzotti E; Tosco A; Cracco C; Scarpa RM; Furlan P; Dogliotti L; Berruti A
Changes in body composition after androgen deprivation therapy (ADT) in prostate cancer patients. Relationship with disease outcome
2008-01-01 A. Berruti; F. Vana; M. Tucci; A. Mosca; L. Russo; G. Gorzegno; A. Saini; P. Perotti; M. Tampellini; L. Dogliotti
Chromogranine A serum levels in patients affected by prostate cancer and benign prostate hypertrophy: comparison between two different commercial kits
2005-01-01 Bosio A; Berruti A; Zitella A; Mengozzi G; Destefanis P; Bisconti A; Casetta G; Aimo P; Rolle L; Greco A; Dogliotti L; Fontana D; Tizzani A
Circadian rhythm of bone turnover markers in breast cancer patients with bone metastases and in control subjects
2005-01-01 D. G. Generali; S. Tedoldi; M. Tampellini; A. Berruti; M. Torta; S. Bonardi; A. Bottini; M. Tucci; M. Milani; A. Angeli; L. Dogliotti
CIRCADIAN RHYTHM OF BONE TURNOVER MARKERS INBREAST CANCER PATIENTS WITH METASTATIC BONE DISEASE ANDIN CONTROL SUBJECTS
2004-01-01 Daniele Generali; Sara Tedoldi; Alberto Bottini; Alfredo Berruti; Marco Tampellini; Marcello Tucci; Giovanni Allevi; Mirella Torta; Simone Bonardi; Manuela Milani; Sergio Aguggini; Alberto Angeli; Luigi Dogliotti
Circadian rhythm of breakthrough cancer pain.
2011-01-01 A. Saini; M. Tucci; K. Bouraouia; P. Ghio; M. Tampellini; P. M. Furlan; L. Ostacoli; L. Dogliotti; A. Berruti
Confronto tra due metodi per la misura della concentrazione della cromogranina A circolante in pazienti con iperplasia prostatica benigna e adenocarcinoma prostatico
2005-01-01 Destefanis P.; Berruti A.; Zitella A.; Mongozzi G.; Rosso R.; Casetta G.; Aimo P.; Rolle L.; Greco A.; Dogliotti L.; Fontana D.; Tizzani A.
Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease.
2006-01-01 Berruti A; Dogliotti L; Tampellini M; Lipton A; Hirsh V; Saad F; Liati P; Shirina N; Cook R; Hei YL
Increased antiresorptive activity of zoledronic acid (Z) administered in the night as compared to morning administration in breast cancer (BC) patients with bone metastases.
2006-01-01 Bottini A; Generali D; Berruti A; Tampellini M; Torta M; Tedoldi S; Bonardi S; Tucci M; Gorzegno G; Dogliotti L
INCREASED NUMBER OF NEUROENDOCRINE CELLS IN METASTATIC COLORECTAL ADENOCARCINOMA FOLLOWING CHEMO/RADIOTHERAPY
2007-01-01 Snezana Andrejevic-Blant; Marco Tampellini; Luisella Righi; Irene Alabiso; Veronica Tavaglione; Marco Volante; Luigi Dogliotti; Mauro Papotti; Valerio Marci
LONG-TERM SURVIVAL OF PATIENTS WITH RESECTION OF PULMONARY METASTASES FROM COLORECTAL NEOPLASMS AS COMPARED TO NOT RESECTED ONES. A RETROSPECTIVE STUDY ON PATIENTS FOLLOWED FROM THE TIME OF FIRST RECURRENCE
2011-01-01 Marco Tampellini; Azzurra Ottone; Elisa Bellini; Irene Alabiso; Francesco Leone; Stefania Miraglia; Oscar Alabiso; Massimo Aglietta; Luigi Dogliotti
Low-dose spiral CT for early diagnosis of lung cancer in a light risk population: 2-year results
2004-01-01 SCAGLIOTTI GV; BORASIO P; DOGLIOTTI L; FAVA C; CORTESE G; CRIDA B; SELVAGGI G; SAINI; CARDINALE L; PLACIDO R; GRIVETTO S; NOVELLO S.
Survival of lung surgery patients with pulmonary metastases from colonic neoplasms
2008-01-01 M. Tampellini; I. Alabiso; A. Ottone; S. Miraglia; L. Forti; E. Bertona; C. M. Sculli; E. Bellini; O. Alabiso; L. Dogliotti
TGFalfa, EGFR and p70S6K expression in aggressive colorectal cancer (CRC)
2006-01-01 M. Tampellini; M. Longo; S. Cappia; E. Bacillo; M. Brizzi; R. Bitossi; C. M. Sculli; I. Alabiso; L. Dogliotti; M. Papotti
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
2006-01-01 A Dovio; D Generali; A Berruti; M Tampellini; S Tedoldi; S Bonardi; M Tucci; G Allevi; S Aguggini; M Milani; A Bottini; L Dogliotti; A Angeli
The importance of monitoring circulating mitotane levels in the management of adrenocortical cancer patients
2009-01-01 Elisa Pirro, Silvia De Francia, Francesca De Martino, Francesca Piccione, Massimo Terzolo, Luigi Dogliotti, Francesco Di Carlo
The onset of skeletal complications in hormone refractory prostate cancer patients is not influenced by the duration of androgen deprivation therapy
2004-01-01 M. Tucci; A. Berruti; A. Mosca; G. La Manna; F. Vana; C. Terrone; M. Tampellini; R. Tarabuzzi; G. Gorzegno; L. Dogliotti
THE ONSET OF SKELETAL COMPLICATIONS IN HORMONEREFRACTORY PROSTATE CANCER PATIENTS IS NOT INFLUENCEDBY THE DURATION OF ANDROGEN DEPRIVATION THERAPY
2004-01-01 Marcello Tucci; Alfredo Berruti; Alessandra Mosca; Federica Vana; Ginevra La Manna; Carlo Terrone; Marco Tampellini; Roberto Tarabuzzi; Gabriella Gorzegno; Roberto Mario Scarpa; Luigi Dogliotti
The role of hemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer (ACC)
2004-01-01 M. Tampellini; A. Saini; I. Alabiso; R. Bitossi; M. P. Brizzi; A. Berruti; G. Gorzegno; S. Miraglia; O. Alabiso; L. Dogliotti
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study | 2012 | Brizzi MP; Fazio N; Ferrero A; Nobili E; Volante M; Tozzi L; D'Avolio A; Milanesi E; Dogliotti L; Berruti A | |
| Case-control study of the impact of adjuvant hormone therapy in prostate cancer patients on quality of life, anxiety and depression and self body image perception | 2008 | Saini A; Ostacoli L; Negro M; Sguazzotti E; Tosco A; Cracco C; Scarpa RM; Furlan P; Dogliotti L; Berruti A | |
| Changes in body composition after androgen deprivation therapy (ADT) in prostate cancer patients. Relationship with disease outcome | 2008 | A. Berruti; F. Vana; M. Tucci; A. Mosca; L. Russo; G. Gorzegno; A. Saini; P. Perotti; M. Tampellini; L. Dogliotti | |
| Chromogranine A serum levels in patients affected by prostate cancer and benign prostate hypertrophy: comparison between two different commercial kits | 2005 | Bosio A; Berruti A; Zitella A; Mengozzi G; Destefanis P; Bisconti A; Casetta G; Aimo P; Rolle L; Greco A; Dogliotti L; Fontana D; Tizzani A | |
| Circadian rhythm of bone turnover markers in breast cancer patients with bone metastases and in control subjects | 2005 | D. G. Generali; S. Tedoldi; M. Tampellini; A. Berruti; M. Torta; S. Bonardi; A. Bottini; M. Tucci; M. Milani; A. Angeli; L. Dogliotti | |
| CIRCADIAN RHYTHM OF BONE TURNOVER MARKERS INBREAST CANCER PATIENTS WITH METASTATIC BONE DISEASE ANDIN CONTROL SUBJECTS | 2004 | Daniele Generali; Sara Tedoldi; Alberto Bottini; Alfredo Berruti; Marco Tampellini; Marcello Tucci; Giovanni Allevi; Mirella Torta; Simone Bonardi; Manuela Milani; Sergio Aguggini; Alberto Angeli; Luigi Dogliotti | |
| Circadian rhythm of breakthrough cancer pain. | 2011 | A. Saini; M. Tucci; K. Bouraouia; P. Ghio; M. Tampellini; P. M. Furlan; L. Ostacoli; L. Dogliotti; A. Berruti | |
| Confronto tra due metodi per la misura della concentrazione della cromogranina A circolante in pazienti con iperplasia prostatica benigna e adenocarcinoma prostatico | 2005 | Destefanis P.; Berruti A.; Zitella A.; Mongozzi G.; Rosso R.; Casetta G.; Aimo P.; Rolle L.; Greco A.; Dogliotti L.; Fontana D.; Tizzani A. | |
| Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease. | 2006 | Berruti A; Dogliotti L; Tampellini M; Lipton A; Hirsh V; Saad F; Liati P; Shirina N; Cook R; Hei YL | |
| Increased antiresorptive activity of zoledronic acid (Z) administered in the night as compared to morning administration in breast cancer (BC) patients with bone metastases. | 2006 | Bottini A; Generali D; Berruti A; Tampellini M; Torta M; Tedoldi S; Bonardi S; Tucci M; Gorzegno G; Dogliotti L | |
| INCREASED NUMBER OF NEUROENDOCRINE CELLS IN METASTATIC COLORECTAL ADENOCARCINOMA FOLLOWING CHEMO/RADIOTHERAPY | 2007 | Snezana Andrejevic-Blant; Marco Tampellini; Luisella Righi; Irene Alabiso; Veronica Tavaglione; Marco Volante; Luigi Dogliotti; Mauro Papotti; Valerio Marci | |
| LONG-TERM SURVIVAL OF PATIENTS WITH RESECTION OF PULMONARY METASTASES FROM COLORECTAL NEOPLASMS AS COMPARED TO NOT RESECTED ONES. A RETROSPECTIVE STUDY ON PATIENTS FOLLOWED FROM THE TIME OF FIRST RECURRENCE | 2011 | Marco Tampellini; Azzurra Ottone; Elisa Bellini; Irene Alabiso; Francesco Leone; Stefania Miraglia; Oscar Alabiso; Massimo Aglietta; Luigi Dogliotti | |
| Low-dose spiral CT for early diagnosis of lung cancer in a light risk population: 2-year results | 2004 | SCAGLIOTTI GV; BORASIO P; DOGLIOTTI L; FAVA C; CORTESE G; CRIDA B; SELVAGGI G; SAINI; CARDINALE L; PLACIDO R; GRIVETTO S; NOVELLO S. | |
| Survival of lung surgery patients with pulmonary metastases from colonic neoplasms | 2008 | M. Tampellini; I. Alabiso; A. Ottone; S. Miraglia; L. Forti; E. Bertona; C. M. Sculli; E. Bellini; O. Alabiso; L. Dogliotti | |
| TGFalfa, EGFR and p70S6K expression in aggressive colorectal cancer (CRC) | 2006 | M. Tampellini; M. Longo; S. Cappia; E. Bacillo; M. Brizzi; R. Bitossi; C. M. Sculli; I. Alabiso; L. Dogliotti; M. Papotti | |
| The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. | 2006 | A Dovio; D Generali; A Berruti; M Tampellini; S Tedoldi; S Bonardi; M Tucci; G Allevi; S Aguggini; M Milani; A Bottini; L Dogliotti; A Angeli | |
| The importance of monitoring circulating mitotane levels in the management of adrenocortical cancer patients | 2009 | Elisa Pirro, Silvia De Francia, Francesca De Martino, Francesca Piccione, Massimo Terzolo, Luigi Dogliotti, Francesco Di Carlo | |
| The onset of skeletal complications in hormone refractory prostate cancer patients is not influenced by the duration of androgen deprivation therapy | 2004 | M. Tucci; A. Berruti; A. Mosca; G. La Manna; F. Vana; C. Terrone; M. Tampellini; R. Tarabuzzi; G. Gorzegno; L. Dogliotti | |
| THE ONSET OF SKELETAL COMPLICATIONS IN HORMONEREFRACTORY PROSTATE CANCER PATIENTS IS NOT INFLUENCEDBY THE DURATION OF ANDROGEN DEPRIVATION THERAPY | 2004 | Marcello Tucci; Alfredo Berruti; Alessandra Mosca; Federica Vana; Ginevra La Manna; Carlo Terrone; Marco Tampellini; Roberto Tarabuzzi; Gabriella Gorzegno; Roberto Mario Scarpa; Luigi Dogliotti | |
| The role of hemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer (ACC) | 2004 | M. Tampellini; A. Saini; I. Alabiso; R. Bitossi; M. P. Brizzi; A. Berruti; G. Gorzegno; S. Miraglia; O. Alabiso; L. Dogliotti |